BRAF and neoplasm: Taken together with other studies [52,53], these results suggest that combining ERK1/2 pathway inhibitors with ER stressors, or ER stress mimetics that influence specific arms of the UPR, may have therapeutic potential in tumours with RAS, BRAF or MEK mutations [9].